- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06335173
En studie för att utvärdera effektivitet och säkerhet av intravenös ACU193 hos deltagare med tidig Alzheimers sjukdom (ALTITUDE-AD) (ALTITUDE-AD)
En fas 2/3 dubbelblind, randomiserad, placebokontrollerad adaptiv designförsök för att utvärdera effektiviteten och säkerheten av intravenös ACU193 vid tidig Alzheimers sjukdom
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Carlsbad, California, Förenta staterna, 92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton, California, Förenta staterna, 92835
- Neurology Center of North Orange County
-
Irvine, California, Förenta staterna, 92614
- Irvine Medical Research
-
Long Beach, California, Förenta staterna, 90804
- Healthy Brain Research
-
Santa Ana, California, Förenta staterna, 92705
- Syrentis Clinical Research
-
Sherman Oaks, California, Förenta staterna, 91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk, Connecticut, Förenta staterna, 06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis, Florida, Förenta staterna, 33462
- JEM Research Institute
-
Bradenton, Florida, Förenta staterna, 34205
- Bradenton Research Center
-
Coral Gables, Florida, Förenta staterna, 33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach, Florida, Förenta staterna, 33445
- Brain Matters Research
-
Homestead, Florida, Förenta staterna, 33032
- Coral Clinical Research
-
Lady Lake, Florida, Förenta staterna, 32159
- K2 Medical Research - Villages
-
Miami, Florida, Förenta staterna, 33126
- Finlay Medical Research
-
Naples, Florida, Förenta staterna, 34105-8522
- Aqualane Clinical Research
-
Ocala, Florida, Förenta staterna, 34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange, Florida, Förenta staterna, 32127
- Progressive Medical Research
-
Stuart, Florida, Förenta staterna, 34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa, Florida, Förenta staterna, 33607
- K2 Medical Research - Tampa
-
The Villages, Florida, Förenta staterna, 32162
- Charter Research - Lady Lake
-
Wellington, Florida, Förenta staterna, 33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park, Florida, Förenta staterna, 32789
- Conquest Research
-
Winter Park, Florida, Förenta staterna, 32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus, Georgia, Förenta staterna, 31909
- Columbus Memory Center
-
Decatur, Georgia, Förenta staterna, 30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook, Illinois, Förenta staterna, 60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton, Massachusetts, Förenta staterna, 02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg, Mississippi, Förenta staterna, 39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth, New Hampshire, Förenta staterna, 03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield, New Jersey, Förenta staterna, 07081
- The Cognitive and Research Center of New Jersey
-
Toms River, New Jersey, Förenta staterna, 08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews, North Carolina, Förenta staterna, 28105
- AMC Research
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97210
- Summit Research Network
-
-
Pennsylvania
-
Abington, Pennsylvania, Förenta staterna, 19001
- Abington Neurological Associates
-
Norristown, Pennsylvania, Förenta staterna, 19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Förenta staterna, 02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova, Tennessee, Förenta staterna, 38018
- Neurology Clinic. P.C
-
Knoxville, Tennessee, Förenta staterna, 37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin, Texas, Förenta staterna, 78757
- Senior Adult Specialty Research
-
Beaumont, Texas, Förenta staterna, 77702
- Gadolin Research, LLC
-
Dallas, Texas, Förenta staterna, 75231
- Kerwin Medical Center
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Kanada
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto, Ontario, Kanada
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park, Quebec, Kanada
- MoCA Research and Innovations
-
-
-
-
-
Barcelona, Spanien
- Fundacio ACE
-
Donostia / San Sebastian, Spanien
- Policlínica Gipuzkoa
-
Getxo, Spanien
- Cae Oroitu
-
Madrid, Spanien
- Hospital Ruber
-
Seville, Spanien
- Hospital Victoria Eugenia
-
Valencia, Spanien
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès, Barcelona, Spanien
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva, Zaragoza, Spanien
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
-
Bristol, Storbritannien
- Re:Cognition Health - Bristol
-
-
Greater London
-
London, Greater London, Storbritannien
- Re:Cognition Health - London
-
London, Greater London, Storbritannien
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester, Hampshire, Storbritannien
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell, Lanarkshire, Storbritannien
- Neuroclin Glasgow
-
-
Lancashire
-
Preston, Lancashire, Storbritannien
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford, Surrey, Storbritannien
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield, Yorkshire, Storbritannien
- Panthera Biopartners - Sheffield
-
-
-
-
-
Berlin, Tyskland
- Charité - Universitaetsmedizin Berlin
-
Cologne, Tyskland
- University Hospital of Cologne
-
Mannheim, Tyskland
- Zentralinstitut für seelische Gesundheit
-
Munich, Tyskland
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
Experimentell: DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
Placebo-jämförare: DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
Experimentell: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Tidsram: Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Antal deltagare med behandlingsrelaterade biverkningar (TEAE)
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Antal deltagare med allvarliga biverkningar (SAE) och biverkningar av särskilt intresse (AESI)
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Antal deltagare som avbryter eller drar sig ur på grund av TEAE
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Antal deltagare med anti-drogantikroppar (ADA) och neutraliserande antikroppar
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Antal deltagare med amyloidrelaterad bildavvikelse med ödem/utgjutningar (ARIA-E) och ARIA med blödning/hemosiderindeposition (ARIA-H) mätt med magnetisk resonanstomografi (MRT)
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
CSF-koncentrationer av ACU193 i en delmängd av deltagare
Tidsram: Fram till vecka 76
|
Fram till vecka 76
|
|
|
Förändring från baslinjen i amyloidplackbelastning eller avsättning mätt med positronemissionstomografi (PET) i centiloider
Tidsram: Baslinje fram till vecka 76
|
Baslinje fram till vecka 76
|
|
|
Ändring från baslinjen i volymetrisk magnetisk resonanstomografi (vMRI) av helhjärnvolym, ventrikulär volym och volym av valda regioner av intresse
Tidsram: Baslinje fram till vecka 76
|
Baslinje fram till vecka 76
|
|
|
Förändring från baslinjen i CSF-koncentrationer av amyloid, Tau och andra neurodegenerativa biomarkörer
Tidsram: Baslinje fram till vecka 76
|
Baslinje fram till vecka 76
|
|
|
Förändring från baslinjen i CSF-koncentrationer av amyloid, Tau och andra neurodegenerativa biomarkörer i en undergrupp av deltagare
Tidsram: Baslinje fram till vecka 76
|
Baslinje fram till vecka 76
|
|
|
Förändring från baslinjen i blodkoncentrationer av amyloid, Tau och andra neurodegenerativa biomarkörer
Tidsram: Baslinje fram till vecka 76
|
Baslinje fram till vecka 76
|
|
|
Effekt av sabirnetug på klinisk progression jämfört med placebo bedömd med tidsbesparingsanalys mätt med iADRS
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Effekt av sabirnetug på klinisk progression jämfört med placebo bedömd med tidsbesparingsanalys mätt med ADCS-iADL
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Effekt av sabirnetug på klinisk progression jämfört med placebo bedömd med tidsbesparingsanalys mätt med ADAS-Cog13
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Effekt av sabirnetug på klinisk progression jämfört med placebo bedömd med tidsbesparingsanalys mätt med CDR-SB
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Effekt av sabirnetug på klinisk progression jämfört med placebo bedömd med tidsbesparingsanalys mätt med MMSE
Tidsram: Baslinje fram till vecka 80
|
Baslinje fram till vecka 80
|
|
|
Serum Koncentration av sabirnetug
Tidsram: Fördosering och flera tidpunkter efter dos upp till 80 veckor
|
Fördosering och flera tidpunkter efter dos upp till 80 veckor
|
|
|
Koncentration av sabirnetug i cerebrospinalvätska (CSF)
Tidsram: Fram till vecka 76
|
Fram till vecka 76
|
|
|
Målengagemang bedömd genom mätning av sabirnetug-amyloid-β oligomer (AβO) komplex i CSF
Tidsram: Fram till vecka 76
|
Fram till vecka 76
|
|
|
Change from Baseline in ADCS-iADL Score
Tidsram: Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
Tidsram: Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Tidsram: Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
Tidsram: Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
Tidsram: Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
Tidsram: Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
Tidsram: Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
Tidsram: Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
Tidsram: Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
Tidsram: Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsram: Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
Tidsram: Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
Tidsram: Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neurologiska manifestationer
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Mentala störningar
- Neurobehavioral manifestationer
- Neurokognitiva störningar
- Kognitionsstörningar
- Demens
- Tauopatier
- Neurodegenerativa sjukdomar
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Kognitiv dysfunktion
- Alzheimers sjukdom
- Minnesstörningar
Andra studie-ID-nummer
- ACU193-201
- 2023-509807-34-00 (Registeridentifierare: EU CT Number)
- 2023 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .